Christopher Mutz - 06 Mar 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
HEAD OF RARE DISEASE
Signature
/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook
Issuer symbol
ANIP
Transactions as of
06 Mar 2026
Net transactions value
-$424,617
Form type
4
Filing time
10 Mar 2026, 16:09:44 UTC
Previous filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mutz Christopher HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE /s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook 10 Mar 2026 0001846487

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Sale $157,421 -2,121 -2% $74.22 101,387 06 Mar 2026 Direct F1, F2
transaction ANIP Common Stock Tax liability -3,314 -3.3% $74.04* 98,073 07 Mar 2026 Direct F3
transaction ANIP Common Stock Sale $267,196 -3,602 -3.7% $74.18 94,471 09 Mar 2026 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
F2 The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.
F3 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.
F4 The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.